Amy Jessop has contributed to harm reduction organizations and hepatitis and health services research for more than 20 years. She is currently the Director of Research and HepTREC at Prevention Point Philadelphia, a large , U.S.-based multi-service harm reduction organization.

Natasha has worked in substance misuse for 15 years. In her current role as Wessex Peer Programme Manager she leads a team of staff and volunteers with lived experience of HCV to help reduce barriers, dispel myths and promote testing.

Lee has led the Southern England and Wales Hepatitis C Trust Prison Peer project for over 5 years. He has also worked in substance misuse and criminal justice field for over 10 years. He has lived experience of hepatitis C, imprisonment and is in long-term recovery from addiction.

Dr. Spencer is a translational clinician-scientist focused on achieving health equity by ending the syndemics afflicting people who use drugs (PWUD). He researches telemedicine-based HIV prevention and HCV treatment in rural PWUD. He practices general internal medicine and HIV medicine at Oregon Health & Sciences University in Portland, Oregon.

Wendy Mitchell, NHS Forth Valley (NHSFV) BBV Community Champion. I have worked with NHSFV for 27 years, almost exclusively with Blood Borne Virus (BBV) Team. As a lifelong Forth Valley resident, I am committed to ensuring all our people affected by BBV’s have the same access to testing and treatment.

David has worked for Gilead Sciences since 2008 in a variety of roles across the UK and Ireland. He has been in his current role of Associate Director Market Access and Policy since June 2019. He is responsible for bringing new drugs to market in Scotland and working with policy makers to improve conditions for people living with HIV, Viral Hepatitis, Cell Therapy and Cancer. Prior to this, David worked as Associate Director – Patient Access to Care (UK and Ireland) where he was part of the team who developed the ground breaking ‘Hepatitis C Elimination Tender’ with NHS England: a unique partnership between the NHS, Pharmaceutical Industry and Third Sector which aims to eliminate HCV in England by 2025. Over the past 11 years David has developed several successful campaigns and projects to educate, raise awareness, test and link patients with HIV and HCV to care.